Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06DOJ
|
|||
| Drug Name |
Seribantumab
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | ||
| Company |
Merrimack Pharmaceuticals Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | Antagonist | [1] |
| KEGG Pathway | ErbB signaling pathway | |||
| Calcium signaling pathway | ||||
| Endocytosis | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| EGF receptor signaling pathway | ||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
| ErbB receptor signaling network | ||||
| a6b1 and a6b4 Integrin signaling | ||||
| WikiPathways | ErbB Signaling Pathway | |||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Signaling Pathways in Glioblastoma | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| Heart Development | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.